Abstract 110P
Background
The CAPSTONE-1 study established adebrelimab combined with carboplatin and etoposide as the first-line standard of care for patients with extensive-stage small-cell lung cancer (ES-SCLC) in China; however, the clinical outcomes of adebrelimab in routine practice remain largely unknown, particularly among patients with brain metastases. Here, we present the first evaluation of the safety and effectiveness of adebrelimab for the first-line treatment of ES-SCLC in a real-world setting.
Methods
In this prospective, multicenter, observational study in China, patients with ES-SCLC who were scheduled to receive adebrelimab-based first-line treatment at the discretion of the investigator were included. The primary outcome was safety profiles according to CTCAE version 5.0. Secondary outcomes included objective response rate (ORR), disease control rate (DCR), duration of response, progression-free survival (PFS), and overall survival (OS).
Results
Between March 9, 2023 and May 7, 2024, 188 patients were included (median age 64 years [range 41-85], 158 [84%] males, 65 [34.6%] current smokers, 42 [22.3%] with brain metastases, 52 [27.7%] with liver metastases, and 79 [42.0%] with pleural effusion). As of August 21, 2024, the median follow-up duration was 5.6 months (IQR 4.1-7.8). Among the 188 patients, the real-world ORR was 65.4% (95% CI 58.2-72.2, and the real-world DCR was 85.1% (95% CI 79.2-89.9). Median PFS was 6.9 months (95% CI 5.8-7.2), with a 6-month PFS rate of 56.9% (95% CI 48.0-64.9). Median PFS was 5.4 months (95% CI 4.8-7.5) in patients with brain metastases and 7.0 months (95% CI 5.9-7.6) in those without brain metastases, without statistical difference (P=0.110). OS data are not mature yet. Treatment-emergent adverse events (TEAEs) of any grade were reported in 166 (88.3%) patients, and grade 3 or worse TEAEs occurred in 60 (31.9%) patients.
Conclusions
This real-world study enrolled a broader and more diverse SCLC patient population compared to the CAPSTONE-1 trial. Despite this, adebrelimab-based regimen showed favorable effectiveness and a manageable safety profile in the first-line setting for ES-SCLC, offering additional pivotal data to the CAPSTONE-1 trial.
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Advancing pre-clinical functional tests with immune-responsive Precision Cut Bladder Tumor Slices (PCTS)
Presenter: Sarah Richtmann
Session: Poster Display session
Resources:
Abstract
206P - Characterisation of tumour-infiltrating lymphocytes (TILs) in liver metastases (LM) and primary tumour (PT) of microsatellite stable (MSS) colorectal cancers
Presenter: Yi Hua Low
Session: Poster Display session
Resources:
Abstract
207P - ZEB2 inhibition relieves TAMs-mediated immunosuppression in EGFR-TKI resistant NSCLC
Presenter: Yunhuan Liu
Session: Poster Display session
Resources:
Abstract
208P - Targeting pro-tumor TAMs to improve immune checkpoint response of advanced bladder cancer
Presenter: Marine Leblond
Session: Poster Display session
Resources:
Abstract
209P - Mapping the landscape of immune cells for optimal index calculation using AI-powered image analysis of multiplexed immunohistochemistry in breast cancer patients
Presenter: Patricia Nielsen
Session: Poster Display session
Resources:
Abstract
210P - Precision immuno-oncology strategies to overcome drug resistance in non-small cell lung cancer
Presenter: Heidi Haikala
Session: Poster Display session
Resources:
Abstract
211P - Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis
Presenter: Haoxin Peng
Session: Poster Display session
Resources:
Abstract
212P - YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer
Presenter: Zhehui Zhu
Session: Poster Display session
Resources:
Abstract
214P - DNA-damaging therapies trigger transcriptome and metabolism changes in peripheral NK cells of SCLC patients
Presenter: Caterina de Rosa
Session: Poster Display session
Resources:
Abstract
215P - Differential spatial gene expression and clinicopathologic characteristics are associated with exceptional response to immune checkpoint inhibition in recurrent/metastatic head and neck cancer
Presenter: Niki Gavrielatou
Session: Poster Display session
Resources:
Abstract